Nicotine therapeutic benefits: Difference between revisions

Line 1,135: Line 1,135:
*[https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1528-1167.2012.03715.x PDF Version]
*[https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1528-1167.2012.03715.x PDF Version]
**Citation: Zerem, A., Nishri, D., Yosef, Y., Blumkin, L., Lev, D., Leshinsky‐Silver, E., Kivity, S. and Lerman‐Sagie, T. (2013), Resolution of epileptic encephalopathy following treatment with transdermal nicotine. Epilepsia, 54: e13-e15. doi: 10.1111/j.1528-1167.2012.03715.x
**Citation: Zerem, A., Nishri, D., Yosef, Y., Blumkin, L., Lev, D., Leshinsky‐Silver, E., Kivity, S. and Lerman‐Sagie, T. (2013), Resolution of epileptic encephalopathy following treatment with transdermal nicotine. Epilepsia, 54: e13-e15. doi: 10.1111/j.1528-1167.2012.03715.x
===2006 [https://pubmed.ncbi.nlm.nih.gov/16931165/ Tobacco habits modulate autosomal dominant nocturnal frontal lobe epilepsy]===
*"This study indicates that nicotine consumption is an environmental factor that, in many patients with ADNFLE, may influence susceptibility to seizures. A detailed account of tobacco habits should be part of the history. Transdermal nicotine should be considered in pharmacoresistant cases."
*[https://sci-hub.se/10.1016/j.yebeh.2006.07.008 PDF Full study]
**Citation: Brodtkorb E, Picard F. Tobacco habits modulate autosomal dominant nocturnal frontal lobe epilepsy. Epilepsy Behav. 2006 Nov;9(3):515-20. doi: 10.1016/j.yebeh.2006.07.008. Epub 2006 Aug 22. PMID: 16931165.


===2003 [https://onlinelibrary.wiley.com/doi/full/10.1046/j.1528-1157.2003.58102.x-i1?sid=nlm%3Apubmed Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study]===  
===2003 [https://onlinelibrary.wiley.com/doi/full/10.1046/j.1528-1157.2003.58102.x-i1?sid=nlm%3Apubmed Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study]===